用含2.5%透明质酸凝胶的3.0%双氯芬酸局部治疗光化性角化病：关于其疗效和安全性累积证据的文献综述
Topical treatment of actinic keratosis with 3.0% diclofenac in 2.5% hyaluronan gel: review of the literature about the cumulative evidence of its efficacy and safety.
作者信息
Javor Sanja, Cozzani Emanuele, Parodi Aurora
机构信息
DISSAL, Department of Dermatology, IRCCS-AOU S. Martino-IST, University of Genoa, Genoa, Italy -
出版信息
G Ital Dermatol Venereol. 2016 Jun;151(3):275-80. Epub 2015 Oct 29.
BACKGROUND
Topical 3% diclofenac in 2.5% hyaluronic acid (HA) gel is a nonsteroidal anti-inflammatory drug approved for the treatment of actinic keratosis (AK). It has been shown to be a safe and effective for treatment of AK on both skin and mucosal lip.
EVIDENCE ACQUISITION
A PubMed search was carried out from 1997 to 2015 using key words in multiple combinations.
EVIDENCE SYNTHESIS
Different studies from the literature shown the efficacy and safety of HA in both immunocompetent and immunosuppressed patients, with important impact on preventing field cancerization. In different clinical trials, the product was effective in significantly reducing lesions when applied for 60 or 90 days.
CONCLUSIONS
Despite the effectiveness of the treatment with topical 3% diclofenac in 2.5% HA, the patients who achieve the complete clinical response should be adequately educated to continue their photoprotection in order to minimize recurrence of AK.
背景
含2.5%透明质酸（HA）的3%双氯芬酸局部凝胶是一种被批准用于治疗光化性角化病（AK）的非甾体抗炎药。已证明其在治疗皮肤和黏膜唇部的AK方面安全有效。
证据收集
于1997年至2015年使用多种关键词组合在PubMed上进行检索。
证据综合
文献中的不同研究表明HA在免疫功能正常和免疫抑制患者中均具有疗效和安全性，对预防场癌化有重要影响。在不同的临床试验中，该产品在应用60天或90天时能有效显著减少病变。
结论
尽管含2.5%HA的3%双氯芬酸局部治疗有效，但对于获得完全临床缓解的患者，应进行充分教育以继续进行光防护，从而将AK的复发降至最低。
Zotero 插件